STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de novo metastatic HSPC (Ng et al, 2020). The five-year overall survival rate for metastatic HSPC remains only 29.8% (Hahn et al, 2018). The treatment of metastatic HSPC has expanded dramatically in recent years with the introduction of several novel therapies. With an array of treatments available, including androgen deprivation therapy (ADT), chemotherapy, and second-generation antiandrogens such as abiraterone, enzalutamide, and apalutamide, clinicians face the challenge of determining the optimal sequencing of therapies for individual patients, with limited data to guide treatment choices (Ng et al, 2020).
Oncologists, urologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with hormone-sensitive prostate cancer (HSPC).
Upon completion of this activity, participants should be able to:
Oliver Sartor, MD (Chairperson)
Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research
Tulane University School of Medicine
Pedro Barata, MD, MSc
Assistant Professor of Medicine
Tulane Cancer Center
Russell Pachynski, MD
Assistant Professor of Medicine
Washington University School of Medicine
There is no fee to participate in or claim CME/NCPD credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Oliver Sartor discloses that he has served as a consultant for Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Janssen, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, and Theragnostics. He has also received research support from Advanced Accelerator Applications, AstraZeneca, Bayer, Constellation, Dendreon, Endocyte, Innocrin, Invitae, Janssen, Merck, Progenics, Sanofi, and SOTIO.
Pedro Barata, MD, MSc, has no disclosures.
Russell Pachynski, MD, has served on the advisory board/panel for BMB, Bayer, EMD Berono/Pfizer, Jounce, AstraZeneca, Janssen, Dendreon, Genomic Health, and Sanoli. He has also served as speaker's bureau for Dendreon, AstraZeneca, Genentech/ROche, Merck, Genomic Health, and Sanoli. received research support from Janssen, BMS, Bavarian Nordic, and Pharmacyclics.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health and USF Health require CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Sanofi Genzyme.
Aggregate participant data will be shared with commercial supporters of this activity.